Icosapent ethyl is a prescription-grade derivative of the omega-3 fatty acid eicosapentaenoic acid, a component of fish oil. Icosapent ethyl may be used for the management of severe ...

Amarin Corporation announced the publication of new data in the Journal of the American Heart Association, detailing a post-hoc analysis from the REDUCE-IT study, which found that Icosapent Ethyl ...

Icosapent Ethyl is a synthetic derivate of the omega-3 fatty acid eicosapentaenoic acid (EPA), prescribed as an adjunct to diet to reduce hypertriglyceridemia in adults.

Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of morbidity and mortality worldwide. Cardiovascular (CV) risk reduction is important in patients at high risk for a first ...

DUBLIN and BRIDGEWATER, N.J., March 12, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), today announced financial results for the fourth quarter of 2024 and provided a review of fourth ...

In draft guidance, the health technology assessment (HTA) organisation has recommended Vazkepa (icosapent ethyl) as a treatment option for adult patients with high-risk cardiovascular disease and ...

The Medicines and Healthcare products Regulatory Agency (MHRA) granted a marketing authorisation for Vazkepa (icosapent ethyl) as a treatment to reduce risk of cardiovascular events in high-risk ...

Austrian Health Authorities Approve VAZKEPA® (icosapent ethyl) for National Reimbursement to Reduce Risk of Cardiovascular Events in Eligible Patients-- -- Effective 1 April 2025, Austrian ...

The data focus on the mechanistic activities of eicosapentaenoic acid (EPA), the active ingredient in Amarin’s icosapent ethyl product, VASCEPA/VAZKEPA, which is used to reduce cardiovascular ...